Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00181714 · ClinicalTrials.gov registry record · Phase 4
Prevention of Cigarette Smoking in Attention Deficit Hyperactivity Disorder (ADHD) Youth With Concerta
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 203
- Enrollment target
NCT00181714: Completed Phase 4 study, sponsored by Massachusetts General Hospital.
NCT00181714 is a Phase 4 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 203 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00181714, a Phase 4 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 203 participants
- Enrollment target
Study Summary
This study will consist of a six-week open-label treatment period with an extended duration methylphenidate (OROS MPH) followed by subsequent monthly visits for 24 months in a large sample of youths aged 12-17 who meet Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for ADHD. The researchers hypothesize that OROS MPH treatment will be associated with low rates of cigarette smoking in ADHD youth.
Interventions
- DRUG methylphenidate HCl (Concerta)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 203 participants |
| Start Date | 2003-11 |
| Est. Completion | 2011-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00181714
The ClinicalTrials.gov registry entry for NCT00181714 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 203 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which methylphenidate HCl (Concerta) is the first listed.
NCT00181714 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00181714 about?
NCT00181714 is a clinical study titled "Prevention of Cigarette Smoking in Attention Deficit Hyperactivity Disorder (ADHD) Youth With Concerta". This study will consist of a six-week open-label treatment period with an extended duration methylphenidate (OROS MPH) followed by subsequent monthly visits for 24 months in a large sample of youths aged 12-17 who meet Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) cr...
What is the current status of trial NCT00181714?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 203 participants. The study started on 2003-11. Estimated completion is 2011-01.
What interventions are being tested in trial NCT00181714?
The interventions under investigation include: methylphenidate HCl (Concerta) (DRUG).
Who is sponsoring clinical trial NCT00181714?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.